Up to 80% of online peptides are adulterated. Telehealth platforms are profiteering without proper science. Review the clinical governance imperatives for Australian practitioners.
The Gray Market: Quality Adrift
Most therapeutic peptides used in wellness, longevity, and performance medicine are not listed on the Australian Register of Therapeutic Goods (ARTG). They are compounded by pharmacies for individual patients under a prescription‑based access pathway. While this pathway is legal, it shifts the quality‑assurance burden onto the prescriber and the compounding pharmacy. A Certificate of Analysis (CoA) verifying identity, purity, endotoxin levels, and sterility should accompany every batch, but this is not a regulatory guarantee. In practice, quality varies enormously.
The 80% adulteration figure from the anti‑doping world may be the most quoted statistic, but it aligns with broader concerns. A 2014 analysis in EuPA Open Proteomics noted that the peptide supply chain often lacks the rigorous Good Manufacturing Practice (GMP) standards applied to approved pharmaceuticals. Shortcuts in solid‑phase peptide synthesis, deletion sequences, incomplete deprotection, residual trifluoroacetic acid, can produce immunogenic impurities. For injectable peptides, sterility is paramount, yet compounding-as-usual may not replicate the sterility assurance of large‑scale GMP production.
Clinically, the stakes are high. A patient self‑injecting a counterfeit or contaminated peptide assumes a therapy is clinically indicated, when in fact the substance may be a different sequence entirely, or may contain microbial endotoxins that trigger systemic reactions. The peer‑reviewed literature contains case reports of adverse events linked to unregulated peptide use, including anaphylaxis, renal impairment, and endocrine disruption. The lesson is not that peptides are inherently dangerous; it is that quality cannot be assumed, it must be verified.
Telehealth and the Profit Motive
The last five years have seen an explosion of Australian telehealth companies advertising peptide‑based protocols for weight loss, muscle gain, skin health, and “anti‑ageing.” Social media marketing often leads with before‑and‑after imagery and aggressive direct‑response funnels. The business model is simple: a patient completes an online questionnaire, pays a fee, and receives a prescription, often without a video consultation, without baseline bloods, and without a documented clinical rationale beyond the patient’s goals.
This is antithetical to sound medical practice. Consider growth hormone secretagogues. CJC‑1295 and Ipamorelin, for instance, can raise insulin‑like growth factor‑1 (IGF‑1) into supraphysiological ranges if dosed indiscriminately. Elevated IGF‑1 is associated with an increased risk of certain cancers, and even transient elevations can uncover undiagnosed insulin resistance or obstructive sleep apnoea. Prescribing such agents without a fasting glucose, HbA1c, age‑specific IGF‑1, and a thorough malignancy and sleep screen is reckless.
Yet many telehealth platforms operate on the assumption that peptides are “natural” and therefore low‑risk. This misunderstands the pharmacology. A peptide is a signalling molecule. It engages receptor systems that have evolved for precise, pulsatile control. Chronic, unmonitored agonism can lead to receptor desensitisation, endocrine feedback disruption, and cascading off‑target effects that a prescriber who never sees the patient’s serial labs will miss.
The profit incentive can also distort clinical decision‑making. When a doctor has a financial stake in a compounding pharmacy or receives volume‑based commissions, the risk of unnecessary prescribing rises. The Medical Board of Australia’s code of conduct is unequivocal: financial arrangements must not compromise patient care. Transparent documentation of any commercial relationship is a minimum standard.
Regulatory Reality for Australian Prescribers
Australian regulation of therapeutic peptides is layered. The Therapeutic Goods Administration (TGA) categorises most compounded peptides as unapproved medicines: they have not been evaluated for safety, quality, or efficacy as finished pharmaceutical products. The Poisons Standard may classify some peptides as Schedule 4 or Schedule 4D, imposing additional prescribing controls and supply limits that vary by state and territory.
The compounding pathway is lawful only when a valid prescription is issued for an individual named patient, no suitable ARTG‑listed alternative exists, and the compounding pharmacy complies with professional practice standards. Several state health departments have recently issued formal warnings about compounded peptide use in cosmetic and wellness settings, a sign of increasing regulatory scrutiny.
AHPRA advertising guidelines further constrain what clinicians can say publicly. Any promotional content must be factual, balanced, and not misleading. It must not create unreasonable expectations of benefit, use testimonials, or encourage demand for a specific unapproved product. Many peptide‑focused telehealth companies fail this test routinely, yet enforcement is reactive rather than proactive.
The international context offers instructive parallels. The US FDA’s 503A compounding pathway classifies bulk drug substances into categories; Category 2 substances have identified safety concerns and expose compounding pharmacies to enforcement action. Several peptides popular in Australia, including ibutamoren (MK‑677), have been placed in that more restrictive category. Australian prescribers should be aware of these signals, even though FDA classifications do not directly apply here.
Clinical Governance: Your Responsibility
If a clinician chooses to prescribe a compounded peptide, the governance requirements are substantial, more demanding than for an approved medicine, because the regulatory safety net is absent. Key obligations include:
- Informed consent. The patient must understand the therapy is unapproved, not TGA‑evaluated, and that not all risks are known. This is a process, not a signature on a form.
- Defensible documentation. The clinical record should clearly state the indication, the evidence grade (established, off‑label, or investigational), ARTG‑listed alternatives considered and why they were unsuitable, and the planned monitoring schedule.
- Baseline investigations. For GH secretagogues, this means fasting glucose, HbA1c, age‑specific IGF‑1, and a relevant hormone panel. For GLP‑1 agonists, renal function and thyroid history are essential. Without these, you cannot assess safety or measure response.
- Monitoring and exit criteria. What will you track, and at what interval? At what point, supraphysiological IGF‑1, onset of oedema, no objective improvement by 12 weeks, do you reduce the dose or stop?
These are not aspirational ideals. They are the building blocks of a defensible practice. In the event of an adverse outcome, the clinical record is your primary evidence. A note that says “Patient wants peptides for anti‑ageing; prescribed CJC/Ipa per protocol” will not withstand scrutiny from AHPRA or a coroner.
A Return to First Principles
The peptide conversation often gets lost in compound names and dosing schedules. The more important conversation is about the clinician’s mindset. Are we prescribing because a patient requested it, or because a thorough assessment identified a specific, measurable deficit that the peptide’s mechanism plausibly addresses? Are we monitoring to confirm benefit, or to justify continuation?
Peptides are not the problem. They are powerful biological signalling molecules with genuine therapeutic potential when used in the right patient, at the right time, with the right oversight. The problem is a market that has normalised them as lifestyle commodities, purchasable with a credit card and a cursory online form.
For Australian doctors and nurse practitioners, the path forward is clear: uphold the same standard of care you would apply to any Schedule 4 medicine. Verify the quality of your compounding pharmacy. Document your clinical reasoning as if it were being read aloud in court. And if a telehealth company offers you a prescribing arrangement that pays per script or discourages follow‑up, decline.
Whether a peptide belongs in your patient’s treatment plan is a decision that demands face‑to‑face (or video) consultation, a structured assessment, and ongoing clinical oversight. This cannot be reduced to a questionnaire and a shopping cart.
General information, not individual medical advice. Speak to your own doctor.